Literature DB >> 8684141

Human parvovirus B19 infection and hepatitis.

S J Naides, Y V Karetnyi, L L Cooling, R S Mark, A N Langnas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8684141     DOI： 10.1016/s0140-6736(96)90720-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Chronic hepatitis caused by persistent parvovirus B19 infection.

Authors:  Trine H Mogensen; Jens Magnus B Jensen; Stephen Hamilton-Dutoit; Carsten S Larsen
Journal:  BMC Infect Dis       Date:  2010-08-20       Impact factor: 3.090

2.  Replication of Aleutian mink disease parvovirus in vivo is influenced by residues in the VP2 protein.

Authors:  J M Fox; M A McCrackin Stevenson; M E Bloom
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 3.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

4.  Parvovirus B19-induced apoptosis of hepatocytes.

Authors:  Brian D Poole; Yuory V Karetnyi; Stanley J Naides
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

5.  The putative metal coordination motif in the endonuclease domain of human Parvovirus B19 NS1 is critical for NS1 induced S phase arrest and DNA damage.

Authors:  Violetta Kivovich; Leona Gilbert; Matti Vuento; Stanley J Naides
Journal:  Int J Biol Sci       Date:  2011-11-24       Impact factor: 6.580

Review 6.  Parvovirus b19 associated hepatitis.

Authors:  Chhagan Bihari; Archana Rastogi; Priyanka Saxena; Devraj Rangegowda; Ashok Chowdhury; Nalini Gupta; Shiv Kumar Sarin
Journal:  Hepat Res Treat       Date:  2013-10-22

7.  Persistence of human parvovirus B19 in tissues from adult individuals: a comparison with serostatus and its clinical utility.

Authors:  R Aravindh; Uma Nahar Saikia; Baijayantimala Mishra; Vandana Kumari; Subhabrata Sarkar; Mirnalini Sharma; Radha Kanta Ratho; Kusum Joshi
Journal:  Arch Virol       Date:  2014-04-30       Impact factor: 2.574
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.